Abrocitinib long-term extension study in moderate to severe atopic dermatitis

Phase 3, open-label trial of abrocitinib in atopic dermatitis (AD) (2 arms), sponsored by Pfizer. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and adverse events leading to discontinuation and 1 more. Started Oct 2018; status: completed.